Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Meta-analysis of the Efficacy and Safety of Grazoprevir and Elbasvir for the Treatment of Hepatitis C Virus Infection

C형 간염 바이러스 감염 치료를 위한 grazoprevir 및 elbasvir의 유효성 및 안전성에 대한 메타 분석

  • Received : 2017.07.03
  • Accepted : 2017.09.22
  • Published : 2017.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Recently, a fixed combination of grazoprevir and elbasvir (GE) has been introduced to the arsenal of chemotherapeutics to fight against this virus. The study aimed to provide information on the efficacy and safety of GE for the treatment of HCV infection by performing a meta-analysis of literature data. Methods: PubMed and EMBASE database searches were conducted. Among the literature retrieved, pivotal Phase III clinical studies were analyzed. Statistical analysis of the data was performed by RevMan. Results: Four pivotal Phase III clinical studies compared the efficacy and safety of GE. When HCV patients were treated with GE for 12 weeks, the sustained virologic response, defined as the viral RNA level below the lower limit of quantification at 12 weeks after the cessation of therapy (SVR12), was 94.7%. The clinical advantage of GE involves its use by patients with cirrhosis and/or renal failure without dose adjustment. If the genotype (GT) of the causative virus was GT1a with NS5A polymorphism or GT4 with resistance to peginterferon/ribavirin, treatment with GE plus ribavirin for 16 weeks resulted in a better outcome compared to treatment with GE alone for 12 weeks. Adverse events reported during the four clinical studies were 71.09% in the GE arms and it was 76.61% in the non-GE arms, with the most frequent events being mild central nervous system symptoms. Conclusion: GE was generally safe and effective for the treatment of HCV infection. However, since HCV mutates very rapidly and becomes resistant to antiviral agents, long-term monitoring should be mandatory.

Keywords

References

  1. World Health Organization. Hepatitis fact sheet. Available from www.who.int/mediacentre/factsheets/fs164/en/. Accessed July 2, 2017.
  2. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology 2013;57:1333-42. https://doi.org/10.1002/hep.26141
  3. World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: Updated version April 2016. Available from https://www.ncbi.nlm.nih.gov/books/NBK362924/. Accessed July 2, 2017.
  4. Manns MP, McHutchison JG, GordonSC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65. https://doi.org/10.1016/S0140-6736(01)06102-5
  5. Nicot F, Alric L, Barange K, et al. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. J Med Virol 2011;83:437-44. https://doi.org/10.1002/jmv.21976
  6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82. https://doi.org/10.1056/NEJMoa020047
  7. AASLD and IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-54. https://doi.org/10.1002/hep.27950
  8. Keating GM. Elbasvir/grazoprevir: First global approval. Drugs 2016;76:617-24. https://doi.org/10.1007/s40265-016-0558-3
  9. Suraweera D, Weeratunga AN, Saab S. Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C. Drug Des Devel Ther 2016;10:2119-27. https://doi.org/10.2147/DDDT.S90537
  10. Landaverde C, Wells J, Hamner R, et al. Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection. Expert Rev Gastroenterol Hepatol 2016;10:419-29. https://doi.org/10.1586/17474124.2016.1147346
  11. U.S. Food & Drug Administration. Prescribing information (Zepatier: Elbasvir and Grazoprevir). Available from http://www.accessdata fda.gov/drugsatfda_docs/label/2016/208261Orig1s000lbl.pdf. Accessed July 2, 2017.
  12. Banerjee D, Reddy KR. Review article: safety and tolerability of directacting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 2016;43:674-96. https://doi.org/10.1111/apt.13514
  13. Ward RP, Kugelmas M. Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Physician 2005;72:655-62.
  14. Carrion AF, Martin P. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C. Expert Opin Drug Saf 2016;15:883-90. https://doi.org/10.1080/14740338.2016.1179278
  15. Alric L, Bonnet D. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection. Expert Opin Pharmacother 2016;17:735-42. https://doi.org/10.1517/14656566.2016.1161028
  16. U.S. Food & Drug Administration. Pharmacology review. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261 Orig1s000PharmR.pdf. Accessed July 2, 2017.
  17. U.S. Food & Drug Administration. Medical review. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/ 208261Orig1s000MedR.pdf. Accessed July 2, 2017.
  18. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1-13. https://doi.org/10.7326/M15-0785
  19. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015;2:319-27. https://doi.org/10.1016/S2352-3018(15)00114-9
  20. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the CSURFER study): a combination phase 3study. Lancet 2015;386:1537-45. https://doi.org/10.1016/S0140-6736(15)00349-9
  21. Kwo P, Gane E, Peng CY, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 2017;152:164-175. https://doi.org/10.1053/j.gastro.2016.09.045
  22. Nakamoto S, Kanda T, Shirasawa H, et al. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol 2015;7:1133-41. https://doi.org/10.4254/wjh.v7.i8.1133
  23. Par A, Par G, Tornai I, et al. IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection. Orv Hetil 2013;154:1261-8. https://doi.org/10.1556/OH.2013.29680
  24. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999;42:2204-12 https://doi.org/10.1002/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D
  25. Tang L, Marcell L, Kottilil S. Systemic manifestations of hepatitis C infection. Infect Agent Cancer 2016;11:29. https://doi.org/10.1186/s13027-016-0076-7
  26. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15. https://doi.org/10.1111/j.1469-0691.2010.03432.x
  27. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011;18:516-22. https://doi.org/10.1111/j.1365-2893.2011.01441.x
  28. Yang HJ, Ryoo JY, Yoo BK. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. Int J Clin Pharm 2015;37:698-708. https://doi.org/10.1007/s11096-015-0144-x
  29. Dugum M, O'Shea R. Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med 2014;81:159-72. https://doi.org/10.3949/ccjm.81a.13155
  30. Bell AM, Wagner JL, Barber KE, et al. Elbasvir/grazoprevir: A review of the latest agent in the fight against hepatitis C. Int J Hepatol 2016;2016:3852126.
  31. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77-87. https://doi.org/10.1002/hep.27259
  32. Deming P, Martin MT, Chan J, et al. Therapeutic advances in HCV genotype 1 infection: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2016;36:203-17. https://doi.org/10.1002/phar.1700
  33. Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol 2013;19:8960-73.
  34. Smolders EJ, de Kanter CT, van Hoek B, et al. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment. Drug Saf 2016;39:589-611. https://doi.org/10.1007/s40264-016-0420-2
  35. U.S. Food & Drug Administration. Clinical pharmacology and biopharmaceutics review. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000ClinPharmR.pdf. Accessed July 2, 2017.
  36. Ferreira VL, AssisJarek NA, Tonin FS, et al. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther 2016;41:478-85. https://doi.org/10.1111/jcpt.12426
  37. Woolston SL, Kim HN. Cost and access to direct-acting antiviral agents. Available from www.hepatitisc.uw.edu/go/evaluation-treatment/cost-access-medications/core-concept/all. Accessed July 2, 2017.
  38. Merck $Helps^{TM}$. Zepatier. Available from http://www.merckhelps.com/ZEPATIER. Accessed July 2, 2017.

Cited by

  1. The Z-Profile Study: a multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in Canadian adult patients with chronic hepatitis C vol.3, pp.3, 2017, https://doi.org/10.3138/canlivj-2019-0029